Bayesian modelling for COVID-19 seroprevalence studies

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study - The Lancet

SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection – A multistage national household survey and modelling study, Dominican Republic, June–October 2021 - The Lancet Regional Health – Americas

SARS-CoV-2 antibody seroprevalence follow-up in Malagasy blood donors during the 2020 COVID-19 Epidemic - eBioMedicine

Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests

A note on COVID-19 seroprevalence studies: a meta-analysis using hierarchical modelling

Using test positivity and reported case rates to estimate state-level COVID-19 prevalence and seroprevalence in the United States

A Continuous Bayesian Model for the Stimulation COVID-19 Epidemic Dynamics

Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2 - ScienceDirect

Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis - The Lancet Global Health

Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys

Extended Bayesian endemic–epidemic models to incorporate mobility data into COVID‐19 forecasting - Douwes‐Schultz - 2022 - Canadian Journal of Statistics - Wiley Online Library

Bayesian modelling for COVID-19 seroprevalence studies

A note on COVID-19 seroprevalence studies: a meta-analysis using hierarchical modelling